Gaby Murphy

Biography

Gaby Murphy is the Managing Director and General Manager of EMD Serono's Canadian operations, where he works to ensure patients across Canada can benefit from the organization's innovative therapies in oncology, neurodegenerative diseases, fertility, and endocrinology.Gaby's expertise comes from more than 20 years of leadership experience in biopharmaceuticals, with significant knowledge in multiple sclerosis (MS) therapies. Earlier in his career, at Teva Pharmaceuticals, he launched the MS drug Copaxone. He first joined EMD Serono as National Sales Director in 2000 and for the next six years, helped to grow the organization's MS portfolio. In 2007, he moved to Novartis Canada, where he built the portfolios of several therapeutic areas, including cardiovascular and neurodegenerative diseases. Between 2009 and 2012, Gaby launched Novartis's MS unit, in particular, GILENYA (fingolimod) and EXTAVIA (interferon beta-1b) brands. His work as Novartis's Regional Neuroscience Head (Latin America and Canada), starting in 2012, saw Gaby championing treatments for MS, Parkinson's and Alzheimer's diseases. After working as the Business Lead, Virology with Bristol Myers Squibb, he rejoined EMD Serono in 2015. Gaby quickly re-established himself among the executive team, as the Head of the Neurodegenerative Diseases Business Unit. He took on his current role leading the Canadian business in November 2015.Gaby holds a Bachelor of Science degree (Biology), with a minor in Economics, from the Université du Québec à Montréal.

Research Interest

treatments for MS, Parkinson's and Alzheimer's diseases